162 related articles for article (PubMed ID: 16595641)
1. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger DM
J Antimicrob Chemother; 2006 Jun; 57(6):1161-7. PubMed ID: 16595641
[TBL] [Abstract][Full Text] [Related]
2. Pyuria in patients treated with indinavir is associated with renal dysfunction.
Sarcletti M; Petter A; Romani N; Lhotta K; König P; Maier H; Zangerle R
Clin Nephrol; 2000 Oct; 54(4):261-70. PubMed ID: 11076101
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
[TBL] [Abstract][Full Text] [Related]
5. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
6. Chronic renal failure among HIV-1-infected patients.
Mocroft A; Kirk O; Gatell J; Reiss P; Gargalianos P; Zilmer K; Beniowski M; Viard JP; Staszewski S; Lundgren JD
AIDS; 2007 May; 21(9):1119-27. PubMed ID: 17502722
[TBL] [Abstract][Full Text] [Related]
7. Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
Collin F; Chêne G; Retout S; Peytavin G; Salmon D; Bouvet E; Raffi F; Garraffo R; Mentré F; Duval X;
Ther Drug Monit; 2007 Apr; 29(2):164-70. PubMed ID: 17417069
[TBL] [Abstract][Full Text] [Related]
8. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Boyd MA; Srasuebkul P; Khongphattanayothin M; Ruxrungtham K; Hassink EA; Duncombe CJ; Ubolyam S; Burger DM; Reiss P; Stek M; Lange J; Cooper DA; Phanuphak P
Antivir Ther; 2006; 11(2):223-32. PubMed ID: 16640103
[TBL] [Abstract][Full Text] [Related]
9. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
Wasmuth JC; Rodermann E; Voigt E; Vogel M; Lauenroth-Mai E; Jessen A; Burger D; Rockstroh JK
Eur J Med Res; 2007 Jul; 12(7):289-94. PubMed ID: 17933700
[TBL] [Abstract][Full Text] [Related]
10. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis.
Saltel E; Angel JB; Futter NG; Walsh WG; O'Rourke K; Mahoney JE
J Urol; 2000 Dec; 164(6):1895-7. PubMed ID: 11061951
[TBL] [Abstract][Full Text] [Related]
11. Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity.
de Araujo M; Seguro AC
Antivir Ther; 2002 Sep; 7(3):181-4. PubMed ID: 12487385
[TBL] [Abstract][Full Text] [Related]
12. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings.
Kopp JB; Falloon J; Filie A; Abati A; King C; Hortin GL; Mican JM; Vaughan E; Miller KD
Clin Infect Dis; 2002 Apr; 34(8):1122-8. PubMed ID: 11915002
[TBL] [Abstract][Full Text] [Related]
13. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity.
Trainor LD; Steinberg JP; Austin GW; Solomon HM
Arch Pathol Lab Med; 1998 Mar; 122(3):256-9. PubMed ID: 9823864
[TBL] [Abstract][Full Text] [Related]
14. [Evidence-based therapeutic drug monitoring for indinavir].
Barrail-Tran A; Taburet AM; Poirier JM;
Therapie; 2011; 66(3):239-46. PubMed ID: 21819808
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
Déti EK; Thiébaut R; Bonnet F; Lawson-Ayayi S; Dupon M; Neau D; Pellegrin JL; Malvy D; Tchamgoué S; Dabis F; Morlat P;
HIV Med; 2010 May; 11(5):308-17. PubMed ID: 20002500
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
17. Indinavir-induced nephropathy.
Grabe DW; Eisele G; Miller C; Singh J; Stein D
Clin Nephrol; 1999 Mar; 51(3):181-3. PubMed ID: 10099891
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Bunupuradah T; van der Lugt J; Kosalaraksa P; Engchanil C; Boonrak P; Puthanakit T; Mengthaisong T; Mahanontharit A; Lumbiganon P; Tompkins E; Burger D; Ruxrungtham K; Ananworanich J;
Antivir Ther; 2009; 14(2):241-8. PubMed ID: 19430099
[TBL] [Abstract][Full Text] [Related]
19. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
20. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria.
Perazella MA; Kashgarian M; Cooney E
Clin Nephrol; 1998 Sep; 50(3):194-6. PubMed ID: 9776425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
